BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] loss -7.55% or -0.35 points to close at $4.22 with a heavy trading volume of 5449148 shares. It opened the trading session at $4.57, the shares rose to $4.6161 and dropped to $4.22, the range by which the price of stock traded the whole day. The daily chart for BCRX points out that the company has recorded 47.21% gains over the past six months. However, it is still -205.8% lower than its most recent low trading price.
If we look at the average trading volume of 10.53M shares, BCRX reached to a volume of 5449148 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BioCryst Pharmaceuticals Inc. [BCRX]:
Barclays have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 05, 2020. While these analysts kept the previous recommendation, BofA/Merrill dropped their target price from $5 to $4. The new note on the price target was released on November 15, 2019, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $16 to $4.50, while RBC Capital Mkts kept a Sector Perform rating on BCRX stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.44, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 15.99. The Price to Book ratio for the last quarter was 211.25, with the Price to Cash per share for the same quarter was set at 0.63.
Trading performance analysis for BCRX stock
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.10. With this latest performance, BCRX shares dropped by -21.90% in over the last four-week period, additionally plugging by 47.21% over the last 6 months – not to mention a rise of 20.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 46.97, with the RSI for the last a single of trading hit 41.53, and the three-weeks RSI is set at 49.77 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 3.90, while it was recorded at 4.34 for the last single week of trading, and 3.00 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -203.66 and a Gross Margin at +91.60. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -222.99.
Return on Total Capital for BCRX is now -85.02, given the latest momentum, and Return on Invested Capital for the company is -135.90. Return on Equity for this stock declined to -248.94, with Return on Assets sitting at -67.61. When it comes to the capital structure of this company, BioCryst Pharmaceuticals Inc. [BCRX] has a Total Debt to Total Equity ratio set at 221.30. Additionally, BCRX Total Debt to Total Capital is recorded at 68.88, with Total Debt to Total Assets ending up at 48.30. Long-Term Debt to Equity for the company is recorded at 116.84, with the Long-Term Debt to Total Capital now at 36.37.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$777,836 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.30.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.40.
BioCryst Pharmaceuticals Inc. [BCRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
An analysis of insider ownership at BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $561 million, or 72.30% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 13,395,617, which is approximately 10.25% of the company’s market cap and around 0.20% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 10,946,166 shares of the stock with an approximate value of $50.02 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $40.09 million in BCRX stock with ownership of nearly 8.009% of the company’s market capitalization.
79 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 21,454,301 shares. Additionally, 66 investors decreased positions by around 41,570,409 shares, while 17 investors held positions by with 59,645,140 shares. The mentioned changes placed institutional holdings at 122,669,850 shares, according to the latest SEC report filing. BCRX stock had 25 new institutional investments in for a total of 6,751,189 shares, while 27 institutional investors sold positions of 11,674,504 shares during the same period.